Document is current
Any future updates will be listed below
-
Authors
McCready, Riley
Morris, Claudia
Antwi-Adjei, Philip
Pourghaed, Mohammed
Sarangi, Ashish
Boles, Annette
Ramirez-Velandia, Felipe
Kopel, Jonathan
Culberson, John https://orcid.org/0000-0002-1112-5672
Singer, Jonathan
Ashworth, Gabriela
Sabbagh, Marwan N.
Neugebauer, Volker
Decourt, Boris
Shin, Andrew C. https://orcid.org/0000-0002-4748-5135
Lawrence, J. Josh https://orcid.org/0000-0002-9068-0841
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG071859)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG073826)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R15AG080446)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG053798)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG053798)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG059008)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (U24AG057437)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (P20AG068053)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG073212)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG059008)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG073212)
TTUHSC School of Medicine Medical Student Summer Research Program
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA197730)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (P20GM109025)
Alzheimer's Drug Discovery Foundation (GC-2013717)
Alzheimer's Drug Discovery Foundation (GC-2013717)
- License Information
-
More Information
Article History
Received: 23 November 2024
Revised: 26 September 2025
Accepted: 26 November 2025
First Online: 3 January 2026
Competing interests
: MNS is a consultant for Roche-Genentech, Eisai, Lilly, Synaptogenix, NeuroTherapia, Signant Health, Novo Nordisk, Prothena, Anavex, Cognito Therapeutics, GSK, and AbbVie. BD is a consultant for Lighthouse Pharmaceuticals.
: All methods were performed in accordance with the relevant guidelines and regulations. Project FRONTIER was approved by the Texas Tech University Health Sciences Center (IRB Number L06-028). Informed consent was obtained from all participants in this study.
